

AXXESS™
SELF-EXPANDING BIFURCATION DES

Raising the standard in bifurcation

Ordering Information

Reference vessel diameter (±0.25 mm)	Stent Length (mm)	
	11	14
3.0	AXBF-3011	AXBF-3014
3.5	AXBF-3511	AXBF-3514

1. Yazdani S.K. et al., "Atheroma and coronary bifurcations: before and after stenting", EuroIntervention Volume 6 Supplement J - FEB 2011 - Coronary Bifurcation Stenting
2. Lefèvre T., Morice M.C. et al, Cathet. Cardiovasc. Intervent. 2000;49:274-283
3. 5-year clinical outcomes of dedicated bifurcation Axxess™ stent in AXXESS PLUS trial, document 11205-000 at Biosensors International
4. 5-year clinical outcomes of dedicated bifurcation Axxess™ stent in DIVERGE trial, document 11203-000 at Biosensors International

Axxess™ Drug Eluting Coronary Bifurcation Stent System is CE approved.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.

Axxess, Biolimus A9 and BA9 are trademarks or registered trademarks of Biosensors International Group, Ltd. All cited trademarks are the property of their respective owners. Les informations relatives à ce produit ne sont pas destinées aux professionnels de santé exerçant en France - Any information related to this product is not intended for health care professionals who practice in France.

Not available for sale in the United States and certain other countries.

© 2013 Biosensors International Group, Ltd. All rights reserved.

www.biosensors.com

BIOSENSORS
INTERNATIONAL™

BIOSENSORS EUROPE SA

Rue de Lausanne 29
1110 Morges
Switzerland
Tel: +41 (0)21 804 80 00
Fax: +41 (0)21 804 80 01

**BIOSENSORS INTERVENTIONAL
TECHNOLOGIES PTE LTD**


Block 10, Kaki Bukit Avenue 1
#06-01/04
Singapore 417942
Tel: +65 6213 5777
Fax: +65 6213 5737

11246000EN - Rev 02



AXXESS™
SELF-EXPANDING BIFURCATION DES

Raising the standard in bifurcation



BIOSENSORS
INTERNATIONAL™

Raising the standard in bifurcation

The role of dedicated bifurcation stents

Bifurcation lesions account for up to 20%¹ of total PCIs, yet there is no formal consensus on how to treat these lesions optimally. Many strategies employ conventional stents by deforming them from their intended design: for example in provisional-T, culotte and crush techniques. Dedicated to bifurcation lesions through its unique design, Axxess offers specific advantages and avoids common pitfalls of conventional stent techniques.

	Axxess	Provisional-T	Culotte/TAP	Crush
Avoiding stent deformation	✓	✗	✗	✗
Preserving SB access	✓	✓	✓	?
Avoiding free-floating struts in ostia of distal branches	✓	✗	✗	✗
Covering and supporting the SB ostium	✓	✓	✓	✓
Avoiding multiple metal layers in bifurcation core	✓	✓	✗	✗
Avoiding gaps between stented segments	✓	✓	✓	✗
Avoiding protrusion of stent material	✓	✓	✗	✗


Axxess™: a simple answer to complex lesions

Axxess is the leading dedicated bifurcation DES

As a drug-eluting stent with abluminal biodegradable polymer, Axxess also uses Biosensors' BA9™ effective anti-restenotic drug to help reduce the higher risk of restenosis associated with bifurcation lesions².




Many cases beside Medina (1,0,0) bifurcations can be treated with a single Axxess stent.



Combined Axxess PLUS and DIVERGE trials^{3,4} (lesions treated with single Axxess)

Excellent and reliable stent apposition due to the self-expanding platform.




Once the stent is placed, the carina is not covered, preserving the anatomy of the bifurcation.




Unlike conventional strategies, Axxess spares the carina

Both 3D and OCT image reconstructions illustrate one of the key points: the Axxess stent prevents a false carina, leaving the flow divider free from stent struts.



Video link




Video link



Video link



Choose the right Axxess for your patients



Courtesy of: OCT images, N.Uren; 3D reconstruction, N.Foin

For illustration purpose only - not to scale